- Report
- January 2022
- 83 Pages
Europe
From €1365EUR$1,500USD£1,160GBP
- Report
- January 2022
- 84 Pages
Middle East, Africa
From €1365EUR$1,500USD£1,160GBP
- Report
- January 2024
- 91 Pages
Global
From €3500EUR$4,119USD£3,077GBP
- Report
- November 2023
- 93 Pages
Global
From €3500EUR$4,119USD£3,077GBP
- Report
- June 2022
- 85 Pages
Global
From €3186EUR$3,500USD£2,706GBP
- Report
- January 2025
- 132 Pages
Global
From €865EUR$950USD£734GBP
- Book
- June 2020
- 198 Pages
- Report
- November 2021
- 527 Pages
Global
From €3641EUR$4,000USD£3,092GBP
- Report
- November 2021
- 365 Pages
Global
From €3186EUR$3,500USD£2,706GBP
- Report
- November 2021
- 802 Pages
Global
From €4551EUR$5,000USD£3,865GBP
- Report
- November 2021
- 1165 Pages
Global
From €5461EUR$6,000USD£4,638GBP
- Report
- July 2024
- 280 Pages
Global
From €1692EUR$1,859USD£1,437GBP
€2416EUR$2,655USD£2,052GBP
- Report
- July 2022
- 315 Pages
Global
From €2447EUR$2,688USD£2,078GBP
€3495EUR$3,840USD£2,969GBP
- Report
- June 2022
- 297 Pages
Global
From €2202EUR$2,419USD£1,870GBP
€3146EUR$3,456USD£2,672GBP
- Report
- December 2021
- 170 Pages
Global
From €2365EUR$2,598USD£2,009GBP
€3379EUR$3,712USD£2,870GBP
- Book
- March 2022
- 896 Pages
- Book
- April 2021
- 288 Pages
- Book
- December 2020
- 432 Pages

The Antisense Oligonucleotide market is a segment of the biotechnology industry that focuses on the development of drugs that use short strands of nucleic acids to target and inhibit the expression of specific genes. These drugs are used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. Antisense oligonucleotides are designed to bind to a specific mRNA sequence, blocking the translation of the gene into a protein. This technology has the potential to revolutionize the treatment of many diseases, as it can be used to target specific genes without affecting other parts of the body.
The Antisense Oligonucleotide market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals. Other companies in the market include Regulus Therapeutics, Dicerna Pharmaceuticals, and Quark Pharmaceuticals. Show Less Read more